skip to main content

There needs to be more diversity in clinical research into anti-migraine drugs. The new generation of migraine drugs has for the most part been tested in a homogeneous population, consisting mainly of American white women with an average BMI of 30-plus. This makes the effect of the medication on people of the opposite sex, stature, ethnicity and age in fact unpredictable. Migraine scientists, Prof. Dr. Antoinette Maassen van den Brink and Dr. Linda Al-Hassany of the Department of Internal Medicine at Erasmus MC, warn against this in an opinion article in the scientific journal The Lancet Neurology. Read the article here.